Advances and challenges in the treatment of lung cancer

被引：183

作者：

Li, Yuting ^{[1
]}

Yan, Bingshuo ^{[1
]}

He, Shiming ^{[1
]}

机构：

[1] Anhui Univ Chinese Med, Sch Integrated Chinese & Western Med, Hefei, Peoples R China

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2023年 / 169卷

关键词：

Lung cancer; Nano drug delivery system; Molecular targeted treatment system; Photothermal treatment strategy; Immunotherapy; CAR-T-CELLS; PHOTOTHERMAL THERAPY; TARGETED THERAPY; CO-DELIVERY; EGFR-TKI; IN-VITRO; LIPID NANOPARTICLES; PLGA NANOPARTICLES; ANTITUMOR IMMUNITY; PD-L1; EXPRESSION;

D O I：

10.1016/j.biopha.2023.115891

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Lung cancer accounts for a relatively high proportion of malignant tumors. As the most prevalent type of lung cancer, non-small cell lung cancer (NSCLC) is characterized by high morbidity and mortality. Presently, the arsenal of treatment strategies encompasses surgical resection, chemotherapy, targeted therapy and radiotherapy. However, despite these options, the prognosis remains distressingly poor with a low 5-year survival rate. Therefore, it is urgent to pursue a paradigm shift in treatment methodologies. In recent years, the advent of sophisticated biotechnologies and interdisciplinary integration has provided innovative approaches for the treatment of lung cancer. This article reviews the cutting-edge developments in the nano drug delivery system, molecular targeted treatment system, photothermal treatment strategy, and immunotherapy for lung cancer. Overall, by systematically summarizing and critically analyzing the latest progress and current challenges in these treatment strategies of lung cancer, we aim to provide a theoretical basis for the development of novel drugs for lung cancer treatment, and thus improve the therapeutic outcomes for lung cancer patients.

引用

页数：18

共 263 条

[1] Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates [J].

Abdelaziz, Hadeer M. ;

Gaber, Mohamed ;

Abd-Elwakil, Mahmoud M. ;

Mabrouk, Moustafa T. ;

Elgohary, Mayada M. ;

Kamel, Nayra M. ;

Kabary, Dalia M. ;

Freag, May S. ;

Samaha, Magda W. ;

Mortada, Sana M. ;

Elkhodairy, Kadria A. ;

Fang, Jia-You ;

Elzoghby, Ahmed O. .

JOURNAL OF CONTROLLED RELEASE, 2018, 269 :374-392

[2] Comparison of oncolytic virotherapy and nanotherapy as two new miRNA delivery approaches in lung cancer [J].

Alvanegh, Akbar Ghorbani ;

Ganji, Shahla Mohammad ;

Kamel, Ali ;

Tavallaie, Mahmood ;

Rafati, Alireza ;

Arpanaei, Ayyoob ;

Dorostkar, Ruhollah ;

Ghaleh, Hadi Esmaeili Gouvarchin .

BIOMEDICINE & PHARMACOTHERAPY, 2021, 140

[3] Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer [J].

Awad, Mark M. ;

Govindan, Ramaswamy ;

Balogh, Kristen N. ;

Spigel, David R. ;

Garon, Edward B. ;

Bushway, Meghan E. ;

Poran, Asaf ;

Sheen, Joong Hyuk ;

Kohler, Victoria ;

Esaulova, Ekaterina ;

Srouji, John ;

Ramesh, Suchitra ;

Vyasamneni, Rohit ;

Karki, Binisha ;

Sciuto, Tracey E. ;

Sethi, Himanshu ;

Dong, Jesse Z. ;

Moles, Melissa A. ;

Manson, Kelledy ;

Rooney, Michael S. ;

Khondker, Zakaria S. ;

DeMario, Mark ;

Gaynor, Richard B. ;

Srinivasan, Lakshmi .

CANCER CELL, 2022, 40 (09) :1010-+

[4] Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer [J].

Bahcall, Magda ;

Awad, Mark M. ;

Sholl, Lynette M. ;

Wilson, Frederick H. ;

Xu, Man ;

Wang, Stephen ;

Palakurthi, Sangeetha ;

Choi, Jihyun ;

Ivanova, Elena V. ;

Leonardi, Giulia C. ;

Ulrich, Bryan C. ;

Paweletz, Cloud P. ;

Kirschmeier, Paul T. ;

Watanabe, Masayuki ;

Baba, Hideo ;

Nishino, Mizuki ;

Nagy, Rebecca J. ;

Lanman, Richard B. ;

Capelletti, Marzia ;

Chambers, Emily S. ;

Redig, Amanda J. ;

VanderLaan, Paul A. ;

Costa, Daniel B. ;

Imamura, Yu ;

Janne, Pasi A. .

CLINICAL CANCER RESEARCH, 2018, 24 (23) :5963-5976

[5] Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer [J].

Blumenschein, George R. ;

Devarakonda, Siddhartha ;

Johnson, Melissa ;

Moreno, Victor ;

Gainor, Justin ;

Edelman, Martin J. ;

Heymach, John, V ;

Govindan, Ramaswamy ;

Bachier, Carlos ;

de Speville, Bernard Doger ;

Frigault, Matthew J. ;

Olszanski, Anthony J. ;

Lam, Vincent K. ;

Hyland, Natalie ;

Navenot, Jean-Marc ;

Fayngerts, Svetlana ;

Wolchinsky, Zohar ;

Broad, Robyn ;

Batrakou, Dzmitry ;

Pentony, Melissa M. ;

Sanderson, Joseph P. ;

Gerry, Andrew ;

Marks, Diane ;

Bai, Jane ;

Holdich, Tom ;

Norry, Elliot ;

Fracasso, Paula M. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)

[6] RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade [J].

Bockorny, Bruno ;

Rusan, Maria ;

Chen, Wankun ;

Liao, Rachel G. ;

Li, Yvonne ;

Piccioni, Federica ;

Wang, Jun ;

Tan, Li ;

Thorner, Aaron R. ;

Li, Tianxia ;

Zhang, Yanxi ;

Miao, Changhong ;

Ovesen, Therese ;

Shapiro, Geoffrey I. ;

Kwiatkowski, David J. ;

Gray, Nathanael S. ;

Meyerson, Matthew ;

Hammerman, Peter S. ;

Bass, Adam J. .

MOLECULAR CANCER THERAPEUTICS, 2018, 17 (07) :1526-1539

[7] FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response [J].

Bogatyrova, Olga ;

Mattsson, Johanna S. M. ;

Ross, Edith M. ;

Sanderson, Michael P. ;

Backman, Max ;

Botling, Johan ;

Brunnstrom, Hans ;

Kurppa, Pinja ;

La Fleur, Linnea ;

Strell, Carina ;

Wilm, Claudia ;

Zimmermann, Astrid ;

Esdar, Christina ;

Micke, Patrick .

EUROPEAN JOURNAL OF CANCER, 2021, 151 :136-149

[8] VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop [J].

Boudria, Asma ;

Abou Faycal, Cherine ;

Jia, Tao ;

Gout, Stephanie ;

Keramidas, Michelle ;

Didier, Chloe ;

Lemaitre, Nicolas ;

Manet, Sandra ;

Coll, Jean-Luc ;

Toffart, Anne-Claire ;

Moro-Sibilot, Denis ;

Albiges-Rizo, Corinne ;

Josserand, Veronique ;

Faurobert, Eva ;

Brambilla, Christian ;

Brambilla, Elisabeth ;

Gazzeri, Sylvie ;

Eymin, Beatrice .

ONCOGENE, 2019, 38 (07) :1050-1066

[9] An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations [J].

Boumelha, Jesse ;

Trecesson, Sophie de Carne ;

Law, Emily K. ;

Romero-Clavijo, Pablo ;

Coelho, Matthew A. ;

Ng, Kevin W. ;

Mugarza, Edurne ;

Moore, Christopher ;

Rana, Sareena ;

Caswell, Deborah R. ;

Murillo, Miguel ;

Hancock, David C. ;

Argyris, Prokopios P. ;

Brown, William L. ;

Durfee, Cameron ;

Larson, Lindsay K. ;

Vogel, Rachel, I ;

Suarez-Bonnet, Alejandro ;

Priestnall, Simon L. ;

East, Philip ;

Ross, Sarah J. ;

Kassiotis, George ;

Molina-Arcas, Miriam ;

Swanton, Charles ;

Harris, Reuben ;

Downward, Julian .

CANCER RESEARCH, 2022, 82 (19) :3435-3448

[10] ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer [J].

Cai, Liangliang ;

Duan, Jianchun ;

Qian, Li ;

Wang, Zhijie ;

Wang, Shuhang ;

Li, Sini ;

Wang, Chao ;

Zhao, Jie ;

Zhang, Xue ;

Bai, Hua ;

Wang, Jie .

FRONTIERS IN IMMUNOLOGY, 2020, 11

← 1 2 3 4 5 6 7 8 9 10 →